Literature DB >> 20450030

Pattern of breast masses in Lagos: a private health facility review of 189 consecutive patients.

E A Jeje1, B O Mofikoya, Y E Oku.   

Abstract

BACKGROUND: The increasing awareness concerning breast cancer has led to significant interest in breast masses in general. As a result there is considerable interest in the clinicopathologic studies of breast masses in various populations.
OBJECTIVE: To study the clinicopathologic pattern of breast masses at a private health facility in Lagos, Nigeria.
METHOD: The records of all patients who presented between January 1993 and December 2002 with breast lumps at the Lagoon Hospital Apapa were reviewed. Their biodata, clinical presentation and histopathological diagnosis were retrieved.
RESULTS: 189 consecutive patients were studied comprising of 180 females and nine males. The peak age incidence for benign disease was 21-30 years while it was 31-40 years for those with malignant masses. Majority (66.1%) presented with painless solitary lumps. 46 (77.2%) patients had benign lumps while 43 (22.8%) had malignant lesions. The commonest benign lesion was fibrocystic disease (47.9%) while infiltrating ductal carcinoma was the commonest pathological diagnosis in the malignant group (83.1%).
CONCLUSION: From this study benign breast masses outnumber malignant ones by more than 3:1 in this population. The commonest pathological diagnosis was fibrocystic disease in benign lesions and infiltrating ductal carcinoma for malignant masses.

Entities:  

Mesh:

Year:  2010        PMID: 20450030     DOI: 10.4314/nqjhm.v20i1.58015

Source DB:  PubMed          Journal:  Nig Q J Hosp Med        ISSN: 0189-2657


  7 in total

1.  Benign and Malignant Breast Disease at Rwanda's First Public Cancer Referral Center.

Authors:  Lydia E Pace; Jean-Marie V Dusengimana; Vedaste Hategekimana; Hamissy Habineza; Jean Bosco Bigirimana; Neo Tapela; Cadet Mutumbira; Egide Mpanumusingo; Jane E Brock; Emily Meserve; Alain Uwumugambi; Deborah Dillon; Nancy L Keating; Lawrence N Shulman; Tharcisse Mpunga
Journal:  Oncologist       Date:  2016-03-23

2.  A longitudinal study of the prevalence and characteristics of breast disorders detected by clinical breast examination during pregnancy and six months postpartum in Ibadan, Southwestern Nigeria.

Authors:  Stella O Odedina; IkeOluwapo O Ajayi; Adenike Adeniji-Sofoluwe; Imran O Morhason-Bello; Dezheng Huo; Olufunmilayo I Olopade; Oladosu A Ojengbede
Journal:  BMC Womens Health       Date:  2018-09-19       Impact factor: 2.809

3.  A five year audit of mammography in a tertiary hospital, North Central Nigeria.

Authors:  Halimat Jumai Akande; Bola Bamidele Olafimihan; Olalekan Ibikun Oyinloye
Journal:  Niger Med J       Date:  2015 May-Jun

4.  Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.

Authors:  Soley Bayraktar; Hongming Qiu; Diane Liu; Yu Shen; Angelica M Gutierrez-Barrera; Banu K Arun; Aysegul A Sahin
Journal:  Biomark Cancer       Date:  2015-08-18

5.  Histopathological features of breast cancer in Al-Madinah region of Saudi Arabia.

Authors:  Abdulkader Albasri; Akbar S Hussainy; Ibrahim Sundkji; Ahmed Alhujaily
Journal:  Saudi Med J       Date:  2014-12       Impact factor: 1.484

6.  Demonstration of an algorithm to overcome health system-related barriers to timely diagnosis of breast diseases in rural Zambia.

Authors:  Leeya F Pinder; Jean-Baptiste Nzayisenga; Aaron Shibemba; Victor Kusweje; Hector Chiboola; Mary Amuyunzu-Nyamongo; Sharon Kapambwe; Catherine Mwaba; Pavlo Lermontov; Chibamba Mumba; Ronda Henry-Tillman; Groesbeck P Parham
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

7.  Age distribution and types of breast lesions among Afghan women diagnosed by fine needle aspiration cytology (FNAC) at a tertiary care centre in Afghanistan: a descriptive cross-sectional study.

Authors:  Ramin Saadaat; Jamshid Abdul-Ghafar; Ahmed Maseh Haidary; Soma Rahmani; Nooria Atta
Journal:  BMJ Open       Date:  2020-09-01       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.